


L.L.C.
BIOINFORMANT

Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends



1ST AND ONLY MARKET RESEARCH FIRM TO
SPECIALIZE IN THE STEM CELL INDUSTRY

TABLE OF CONTENTS

1.	REPORT OVERVIEW.....	17
1.1	Statement of the Report	17
1.2	Executive Summary	19
1.3	Introduction.....	21
2.	CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT	22
2.1	An Overview of CAR-T cell Therapy	23
2.2	Evolution of CAR-T Development	24
2.2.1	CAR-T cell Therapy Technology Progression	24
2.2.1.1	First Generation CARs	25
2.2.1.2	Second Generation CARs.....	26
2.2.1.3	Third Generation CARs.....	26
2.2.1.4	Fourth Generation CARs.....	27
2.2.1.5	Fifth Generation CARs	27
2.3	Antigens Present on Hematological Malignant Cells	28
2.4	Tools for Inserting Receptor Genes into T cells.....	29
2.5	Transforming T cells into CAR-T cells.....	30
2.6	The 13 CAR-T Therapies Available Globally: A Brief Overview	31
2.6.1	Kymriah (tisagenlecleucel)	35
2.6.1.1	Manufacturing.....	36
2.6.1.2	Indication	37
2.6.1.3	Dosage Composition	37
2.6.1.4	Approval History of Kymriah.....	38
2.6.1.5	Sales Revenue	39
2.6.2	Yescarta (axicabtagene ciloleucel).....	39
2.6.2.1	Manufacturing of Yescarta	40
2.6.2.2	Indication	41
2.6.2.3	Dosage Composition	41
2.6.2.4	Approval History of Yescarta.....	41
2.6.2.5	Sales Revenue	43
2.6.3	Tecartus (brexucabtagene autoleucel).....	43
2.6.3.1	Manufacturing of Tecartus	44
2.6.3.2	Indication	45
2.6.3.3	Dosage Composition	45
2.6.3.4	Approval History of Tecartus.....	45
2.6.3.5	Sales Revenue	46
2.6.4	Breyanzi (lysocabtagene maraleucel)	46
2.6.4.1	Manufacturing of Breyanzi	47
2.6.4.2	Indication	48
2.6.4.3	Dosage Composition	48
2.6.4.4	Approval History of Breyanzi.....	48
2.6.4.5	Sales Revenue	50
2.6.5	Abecma (idecabtagene vicleucel)	51
2.6.5.1	Manufacturing of Abecma	51
2.6.5.2	Indications	52
2.6.5.3	Dosage Composition	52
2.6.5.4	Approval History of Abecma.....	52
2.6.5.5	Sales Revenue	53
2.6.6	Relma-cel (relmacabtagene autoleucel).....	54
2.6.7	Carvykti (ciltacabtagene autoleucel)	55
2.6.7.1	Manufacturing of Carvykti	55
2.6.7.2	Indications	56
2.6.7.3	Dosage	57

2.6.7.4	Approval History of Carvykti.....	57
2.6.7.5	Sales Revenue.....	58
2.6.8	Fucaso (equecabtagene autoleucl).....	58
2.6.8.1	Dosage & Overall Response Rate.....	58
2.6.9	NexCAR19 (actalycabtagene autoleucl).....	59
2.6.10	Yuanruida (inaticabtagene autoleucl).....	59
2.6.11	Zevor-cel (zevorcabtagene autoleucl).....	60
2.6.12	Qartemi (varnimcabtagene autoleucl).....	61
2.6.12.1	Indication & Dosage.....	61
2.6.12.2	Product Description & Mechanism of Action.....	61
2.6.12.3	Manufacture.....	62
2.6.13	Aucatzyl (obecabtagene autoleucl).....	62
2.6.13.1	Manufacturing.....	63
2.6.13.2	Indication & Dosage.....	63
2.6.13.3	Approval.....	63
2.6.13.4	Wholesale Price.....	64
2.7	Cost of CAR-T Therapy around the World.....	64
2.8	Toxicities Associated with CAR-T Treatment.....	65
3.	STRATEGIES FOR FUTURE CAR-T THERAPIES.....	66
3.1	Switchable CARs (sCARs/Universal CARs).....	67
3.1.1	Switchable CAR-Ts in the Clinic.....	67
3.1.2	Suicide Genes.....	68
3.1.3	Transient Transfection.....	69
3.2	Affinity-Tuned CARs.....	70
3.3	Armored CARs.....	71
3.4	Shift from Liquid Cancers to Solid Cancers.....	72
3.5	Focus on Shortening Hospital Stay.....	73
3.6	Focus on Discovering New Antigens.....	73
3.7	CAR-T for the Masses.....	74
3.8	New <i>In Vivo</i> CAR-T Approaches.....	74
3.9	Combination with mRNA Vaccine.....	75
3.10	Combination with Oncolytic Virus.....	75
4.	MAJOR EVENTS DURING THE DEVELOPMENT OF CAR-T, 1989 to Present.....	76
4.1	Major 15 Milestones Crossed by CAR-T cell Therapy.....	78
4.1.1	First CAR Developed by Zelig Eshhar (1993).....	78
4.1.2	Development of First Generation CAR-T (1993).....	78
4.1.3	First Effective CAR-T Cells Developed (2002).....	78
4.1.4	Second Generation CARs Developed (2003).....	79
4.1.5	Recipe for CD19 CARs Published (2009).....	79
4.1.6	Coley Award Given for CAR-T Cell Therapy (2012).....	79
4.1.7	Results for CAR-T Leukemia Published (2013).....	79
4.1.8	Cancer Immunotherapy Voted “Breakthrough of the Year” (2013).....	80
4.1.9	FDA Designates CARs a “Breakthrough” Therapy (2014).....	80
4.1.10	Mesothelin-Directed CARs Developed (2014).....	80
4.1.11	Armored CARs Developed (2015).....	80
4.1.12	CRISPR CARs Built (2017).....	80
4.1.13	First CAR-T Crosses Regulatory Finish Line (August 30, 2017).....	81
4.1.14	Second CAR-T Approval (October 18, 2017).....	81
4.1.15	Third CAR-T Approval (July 24, 2020).....	81
4.1.16	Fourth CAR-T Approval (February 5, 2021).....	81
4.1.17	Fifth CAR-T Approval (March 26, 2021).....	82
4.1.18	Sixth CAR-T Approval (September 6, 2021).....	82
4.1.19	Seventh CAR-T Approved (February 28, 2022).....	82
4.1.20	Eighth CAR-T Approval (July 2, 2023).....	82

4.1.21	Ninth CAR-T Approval (October 16, 2023).....	83
4.1.22	Tenth CAR-T Approval (November 8, 2023)	83
4.1.23	Eleventh CAR-T Approval (March 1, 2024).....	83
4.1.24	Twelfth CAR-T Approval (May 7, 2024)	83
4.1.25	Thirteenth CAR-T Approval (November 8, 2024).....	84
4.2	The Upcoming CAR-T Stars	84
4.2.1	ALLO-501 & ALLO-501A.....	85
4.2.2	CTX-110, CTX-112, CTX-130 & CTX-131	85
4.2.3	UCART19	86
4.2.4	AUT01/22.....	86
4.2.5	JCARH125.....	86
4.2.6	PBCAR-20A.....	87
4.2.7	PRGN-3006	87
4.2.8	UCART22	87
4.2.9	UCARTCS1	87
4.3	The Small Cancer Population Addressed by CAR-T	88
4.4	Advantages of CAR-T cell Therapy.....	89
4.5	Disadvantages of CAR-T cell Therapy.....	89
4.6	Success Rate of CAR-T Therapy.....	89
5.	CAR-T TARGETED ANTIGENS	91
5.1	CAR-T Target Antigens in Hematological Cancers.....	92
5.2	CAR-T Target Antigens in Solid Cancers	93
5.3	Most Common Antigens Targeted by CAR-T Cells in Clinical Trials	94
5.3.1	Cluster Differentiation 19 (CD19)	94
5.3.2	Mesothelin	95
5.3.3	Beta Cell Maturation Agent (BCMA).....	95
5.3.4	GD2	95
5.3.5	Glypican-3 (GPC3)	96
5.3.6	Cluster Differentiation-22 (CD22).....	96
6.	SCALABLE MANUFACTURING OF CAR-T CELLS	97
6.1	Manufacturing Process	97
6.1.1	Local & Centralized CAR-T Supply Chain Pathways	99
6.2	The Evolution of CAR-T Manufacturing Platforms	100
6.2.1	Open vs. Closed Systems	100
6.2.2	Manual Processing vs. Automation	100
6.3	Allogeneic CAR-T Manufacturing.....	101
6.4	Currently Used CAR-T Manufacturing Platforms	102
6.4.1	CliniMACS Prodigy	102
6.4.2	Cocoon	103
6.4.3	Xuri Cell Expansion System W25.....	104
6.4.4	G-Rex	104
6.5	Comparison of CAR-T Manufacturing Platforms.....	105
6.6	CAR-T Manufacturing Cost	106
6.6.1	Breakdown of CAR-T Manufacturing Cost	107
7.	CAR-T PATENT LANDSCAPE	108
7.1	Geographical Distribution of CAR-T Cell Therapy Patents	109
7.2	CAR-T Cell Therapy Patent Applicants.....	110
7.3	CAR-T Patent Inventors	113
7.4	CAR-T Cell Therapy Patent Owners	116
7.5	Legal Status of CAR-T Therapy Patents.....	119
7.6	Ways to Extend Patent Life	119
8.	CAR-T CLINICAL TRIAL LANDSCAPE.....	121

8.1	CAR-T Clinical Trials by Phase of Development	121
8.2	Types of CAR-T Clinical Trials	122
8.3	CAR-T Clinical Trials by Funding Type	123
8.4	Types of Hematologic Cancers (Liquid Cancers) Addressed by Clinical Trials.....	123
8.5	Simultaneous Targets by One CAR-T.....	124
8.6	CAR-T Generation Types used in Clinical Trials	125
8.7	CAR-T Trials by SvFv Used	125
8.8	CAR-T Trials by Type of Vectors Used.....	126
8.9	Autologous & Allogeneic CAR-Ts in Clinical Trials	127
8.10	Landscape of Clinical Trials Focusing on Solid Cancers	127
8.10.1	Geographical Distribution of CAR-T Clinical Trials for Solid Tumors	128
8.10.2	Vectors used to Transduce CAR Gene into T Cells	129
9.	RATES, TYPES, AND TRENDS FOR CAR-T CELL THERAPY SCIENTIFIC PAPERS ...	131
9.1	PubMed Papers on Autologous and Allogeneic CAR-T Cell Therapies	132
9.2	CAR-T Cell Therapy for Liquid vs. Solid Cancers, 2013 to Present	133
9.3	PubMed.gov Papers on Five Generations of CAR-T Cell Therapy	134
10.	CAR-T FUNDING LANDSCAPE	135
10.1	Venture Capital Funding in CAR-T Sector, 2014 to Present	135
10.1.1	VC Funding for CAR-T Companies by Year, 2014 to Present	138
10.2	IPO Funding Invested in CAR-T Companies, 2014 to Present.....	139
10.3	CAR-T Licensing Deals	142
10.4	CAR-T Collaboration Deals	145
10.5	CAR-T Merger & Acquisition (M&A) Deals, 2015 to Present.....	149
10.6	Summary of CAR-T Funding.....	150
11.	COST OF CAR-T CELL THERAPY & REIMBURSEMENT	152
11.1	New Payment Models	152
11.2	List Prices of Approved CAR-T Cell Therapies	152
11.2.1	Component Costs Associated with CAR-T Cell Therapy	154
11.2.2	Adverse Events (AEs) Costs	155
11.3	Reimbursement in the U.S. for CAR-T Cell Therapy	156
11.3.1	Medicare Payment Changes in 2025 for CAR-T Cases.....	157
11.3.1.1	High-Cost Outlier Payments	157
11.3.1.2	Adjustment for Clinical Trial Cases.....	157
11.3.1.3	Inpatient & Outpatient Medicare Spend for CAR-T	158
11.4	Cost of CAR-T Therapies in Europe	159
11.4.1	Financing CAR-T Therapies in the E.U.	160
11.4.2	Estimated Cost of CAR-T Therapies in the E.U.	161
11.4.3	Utilization of CAR-T Cell Therapy in Europe	161
11.4.4	Utilization of CAR-T in Europe by Indication	162
11.5	CAR-T Cell Therapy in Asia Pacific (APAC)	163
11.5.1	CAR-T Funding in Australia.....	163
11.5.2	CAR-T Funding in Singapore	164
11.5.3	CAR-T in South East Asia (SEA) [Except in Singapore]	165
11.5.3.1	Cost & Reimbursement for CAR-T in Japan.....	165
11.5.3.2	Cost & Reimbursement for CAR-T in South Korea	165
11.5.3.3	CAR-T Reimbursement in China	166
11.5.3.4	CAR-T Reimbursement in Malaysia	166
11.5.3.5	Cost & Reimbursement for CAR-T in India.....	166
12.	BLOOD CANCERS ADDRESSED BY CAR-T	167
12.1	Acute Lymphoblastic Leukemia (ALL).....	167
12.1.1	Available Therapies for ALL	168
12.2	Diffuse Large B-cell Lymphoma (DLBCL)	168

12.2.1	Available Therapies for DLBCL	169
12.3	Mantle Cell Lymphoma (MCL)	170
12.3.1	Available Therapies for MCL	170
12.4	Multiple Myeloma (MM)	171
12.4.1	Available Therapies for Multiple Myeloma.....	171
12.5.1	Available Therapies for Follicular Lymphoma	172
12.6	The Staggering Cost of Blood Cancer Therapies	173
13.	MARKET ANALYSIS	175
13.1	Global Rates of CAR-T Cell Therapies, 2017-2024.....	175
13.1.1	Current Global Market for CAR-T by Product, 2017-2024	176
13.2	Global Market for CAR-T Cell Therapy Products, 2024-2032	180
13.3	Global Market for CAR-T Therapy by Geography, 2024-2032	182
13.4	Global Market for CAR-T Therapies by Indication, 2024-2032.....	184
13.5	Obstacles to Global Implementation of CAR-T Cell Therapies.....	185
13.5.1	Patient-Related Factors.....	185
13.3.2	Disease Biology Factor.....	186
13.3.3	Adverse Events	186
13.3.4	Cost	187
13.3.5	Manufacturing Chain and Supply	187
13.3.6	Hospitals and Pathways of Care	188
14.	CAR-T COMPNIES: AN OVERVIEW	189
14.1	2seventy bio	189
14.1.1	Abecma (idecabtagene vicleucel)	189
14.2	Abintus Bio, Inc.	190
14.3	Afflymune Therapeutics, Inc.	191
14.3.1	Affinity-Tuned CARs	191
14.3.1.1	ICAM-1: Afflymune’s Target Antigen	192
14.3.1.2	Targeted Indication	192
14.4	Aleta BioTherapeutics	193
14.4.1	Aleta’s CAR-T Engager Pipeline	193
14.5	Allogene Therapeutics	194
14.5.1	AlloCAR-T.....	194
14.5.1.1	Manufacturing of AlloCAR-T	194
14.6	Anixa Biosciences, Inc.	196
14.7	Arbele, Ltd.	197
14.7.1	Advanced Cell Therapy	197
14.8	Arcellx.....	198
14.8.1	D-Domain Technology.....	198
14.8.2	ddCAR Platform.....	198
14.8.3	ARC-SparX Platform	199
14.9	Atara Biotherapeutics	200
14.9.1	Technology	200
14.9.2	Allogeneic CAR-T Programs	201
14.10	Aurora BioPharma	202
14.10.1	HER2 Platform	202
14.11	Autolus Therapeutics plc	203
14.11.1	Technology.....	203
14.11.2	CAR-T Cell Production.....	203
14.11.3	Manufacturing.....	204
14.11.4	Therapies in Development	204
14.11.4.1	obe-cel	204
14.12	AvenCell Europe GmbH.....	205
14.12.1	Universal Switchable CAR	205
14.12.2	Allogeneic Platform	205

14.12.3	Clinical & Preclinical Pipeline Overview	206
14.13	Beam Therapeutics, Inc.	207
14.13.1	BEAM-201	207
14.14	Bellicum Pharmaceuticals	208
14.14.1	GoCAR Technology	208
14.14.2	CaspaCIDE Safety Switch	208
14.15	BioNTech	210
14.15.1	BioNTech's Engineered Cell Therapies	210
14.15.2	BN211	210
14.15.3	BN212	210
14.16	Biosceptre	211
14.16.1	Biosceptre's Unique Target nf2X ⁷	211
14.16.2	BRiDGE CAR Program	211
14.17	Bluebird bio	212
14.17.1	Blebird bio's CAR-T Collaborations	212
14.17.2	Collaboration with BMS	212
14.17.3	Collaboration with TC BioPharm	213
14.17.4	Collaboration with Inhibrx	213
14.17.5	Collaboration with PsiOxus	213
14.18	Bristol Myers Squibb/Celgene Corporation	214
14.18.1	Products	214
14.18.1.1	Abecma (idecabtagene vicleucel)	214
14.18.1.2	Breyanzi (lisocabtagene maraleucel)	214
14.19	Cabaletta Bio	215
14.19.1	CABA Platform	215
14.19.2	Cabaletta's Pipeline	216
14.20	Carina Biotech	217
14.21	CARsgen Therapeutics	218
14.21.1	CycloCAR-T	218
14.21.2	THANK-uCAR	219
14.21.3	LADAR	220
14.22	Cartesian Therapeutics	221
14.22.1	mRNA CAR-T Cell Program (RNA Armory)	221
14.22.2	Pipeline	221
14.23	CARTherics Pty Ltd.	222
14.23.1	Autologous CAR-T Cells	222
14.24	CASI Pharmaceuticals	223
14.24.1	Yuanruida (inaticabtagene autoleucel; CNCT19)	223
14.25	Collectis	224
14.25.1	TAL nucleases, or TALEN	224
14.25.2	Gene Editing	224
14.25.3	PulseAgile Technology	225
14.25.4	Main Product Candidates	225
14.26	Celularity, Inc.	226
14.26.1	P CAR-T	226
14.27	Celyad Oncology	227
14.27.1	NKG2D-Based CAR-T Cells	227
14.27.2	Multispecific CAR	228
14.27.3	Short Hairpin RNA-based Platform	229
14.27.4	CAR-T Therapy Development Services	229
14.27.5	Biomarker Identification and Selection	229
14.27.6	scFv Generation	230
14.27.7	CAR-T Gene Packaging and Delivery	230
14.27.8	Virus Testing Service	230
14.27.9	CAR Cell in vitro Assay Service	231
14.27.10	CAR-T Preclinical in vivo Assay	231

14.27.11	IND Development for CAR-T Cell Therapy	231
14.27.12	GMP Production for CAR-T Products	231
14.27.13	CAR-T Clinical Trial Services.....	232
14.28	CRISPR Therapeutics.....	233
14.28.1	CRISPR Therapeutics' Immuno-Oncology Programs.....	233
14.28.2	CRISPR/Cas9-enabled Allogeneic CAR-T Design	233
14.29	Curocell, Inc.	235
14.29.1	OVIS Technology	235
14.30	DiaCarta	236
14.30.1	Personalized CAR-T Immunotherapy Platform	236
14.31	Elicera Therapeutics AB	237
14.31.1	iTANK CAR-T Technology	237
14.31.2	Elicera's Product Pipeline	238
14.32	EXUMA Biotech	239
14.32.1	TMR CAR-T Technology.....	239
14.32.2	CCT3 CAR-T	239
14.32.3	rPOC SC CAR-TaNKs	240
14.32.4	GCAR "in vivo Cell Therapy".....	240
14.33	Fate Therapeutics	241
14.33.1	FT819.....	241
14.33.2	FT825.....	242
14.34	Galapagos NV.....	243
14.35	Gilead Sciences, Inc.	244
14.35.1	CAR-T Products	244
14.35.1.1	Tecartus (brexucabtagene autoleucl)	244
14.34.1.2	Yescarta (axicabtagene ciloleucl)	244
14.36	Gracell Biotechnologies	245
14.36.1	FasTCAR.....	245
14.36.2	TruUCAR.....	246
14.36.3	SMART CAR-T.....	247
14.36.4	Gracell's Product Pipeline	247
14.37	IASO Biotherapeutics.....	249
14.37.1	Technology Platforms	249
14.37.2	Fully Human Antibody Discovery Platform.....	249
14.37.3	High-Throughput Screening Platform for CAR-T Candidates.....	250
14.37.4	Universal CAR-T Technology Platform	250
14.37.5	CAR-T Manufacturing Technology Platform	250
14.37.6	IASO's Diverse Product Pipeline.....	250
14.38	ImmPACT Bio	252
14.38.1	CD19/20 Bispecific CAR	252
14.38.2	TGF-β.....	253
14.39	Immuneel Therapeutics, Pvt., Ltd.	254
14.39.1	Immuneel's R&D Roadmap.....	254
14.40	ImmunoACT	255
14.40.1	NexCAR19 (Actalycabtagene autoleucl).....	255
14.41	Interius BioTherapeutics	256
14.41.1	Core Technology	256
14.42	Juventas Cell Therapy	257
14.42.1	Yuanruida (inaticabtagene autoleucl)	257
14.43	JW Therapeutics	258
14.43.1	Carteyva (relmacabtagene autoleucl; relma-cel)	258
14.44	Kite Pharma (Gilead)	260
14.44.1	Kite's Marketed CAR-T Products	260
14.44.1.1	Yescarta (axicabtagene ciloleucl)	260
14.44.1.2	Tecartus (brexucabtagene autoleucl)	261
14.44.2	Kite's Pipeline Cancer Therapies	262

14.45	Kyverna Therapeutics	263
14.45.1	Kyverna’s CAR-T Therapy for Autoimmune Diseases.....	263
14.46	Legend Biotech	264
14.46.1	Technology Platforms	264
14.46.1.1	CAR-T	264
14.46.1.2	CAR- $\gamma\delta$ T	265
14.46.1.3	CAR-NK	265
14.46.1.4	Non-Gene-Editing Universal CAR-T	265
14.46.2	Product Pipeline	266
14.47	Leucid Bio	267
14.47.1	Leucid’s Lateral CAR-Platform.....	267
14.47.2	LEU011 – NKG2D CAR-T Cell Therapy	268
14.47.3	T2, $\gamma\delta$ T-Cells for Off-The-Shelf Therapy	269
14.47.4	T4 Immunotherapy	269
14.47.5	Novel Manufacturing Platform.....	270
14.48	Luminary Therapeutics, Inc.	271
14.48.1	Allogeneic Gamma 2.0+ Platform	271
14.48.2	Non-Viral Gene Modification Process	271
14.48.3	Split Co-Stim Dual CAR	272
14.48.4	Ligand-Based CAR to Target Three Antigens	273
14.48.5	Product Pipeline	274
14.49	Lyell Immunopharma, Inc.	275
14.49.1	Technology.....	275
14.49.1.1	Gen-R Technology.....	275
14.49.1.2	Epi-R Technology	276
14.49.2	Lyell’s Product Pipeline.....	276
14.50	March Biosciences.....	277
14.50.1	MB-105.....	277
14.50.2	March Biosciences’ Pipeline	278
14.51	MaxCyte, Inc.	279
14.51.1	Technology: Flow Electroporation.....	279
14.51.2	MaxCyte’s Electroporation Systems	280
14.51.2.1	ATx.....	280
14.51.2.2	GTx	281
14.51.2.3	STx.....	281
14.51.2.4	VLx.....	282
14.52	Minerva Biotechnologies Corporation.....	284
14.52.1	CAR-T (huMNC2-CAR44).....	284
14.53	Mustang Bio	286
14.53.1	Mustang’s CAR-T Focus	286
14.54	Noile-Immune Biotech.....	287
14.54.1	PRIME CAR-T	287
14.55	Novartis AG.....	289
14.55.1	The Pioneer in CAR-T.....	289
14.55.2	Kymriah (tisagenlecleucel)	289
14.55.3	T-Charge Platform.....	290
14.55.3.1	Phase I YTB323 Clinical Study.....	290
14.55.3.2	Phase I PHE 885 Clinical Study	290
14.56	Oncternal Therapeutics.....	291
14.56.1	ONCT-808.....	291
14.57	Oxford Biomedica plc.....	292
14.57.1	LentiVector Platform.....	292
14.57.2	inAAVate Platform	293
14.57.3	CDMO Services.....	293
14.58	PeprMene Bio, Inc.	294
14.58.1	BAFFR CAR-T Cells	294

14.59	Poseida Therapeutics, Inc.	295
14.59.1	Poseida’s Genetic Engineering Platforms.....	295
14.59.2	PiggyBac Platform for Insertion.....	296
14.59.3	Cas-CLOVER Platform for Editing.....	297
14.59.4	Poseida’s CAR-T Product Candidates.....	297
14.60	Precigen, Inc.	298
14.60.1	UltraCAR-T.....	298
14.60.2	Sleeping Beauty System.....	299
14.60.3	UltraPorator System.....	300
14.60.4	Product Pipeline.....	301
14.61	Prescient Therapeutics.....	302
14.61.1	OmniCAR.....	302
14.61.2	CellPryme.....	303
14.62	ProMab Biotechnologies, Inc.	304
14.62.1	ProMab’s CAR-T Cells.....	304
14.62.2	ProMab’s Services.....	305
14.62.3	ProMab’s Preclinical and Clinical Study Services.....	306
14.63	SOTIO Biotech BV.....	307
14.63.1	BOXR Technology.....	307
14.63.2	BOXR1030.....	308
14.64	Syngene International, Ltd.	309
14.64.1	CAR-T Services.....	309
14.65	Synthekine.....	311
14.65.1	STK-009 + SYNCAR-001.....	311
14.66	TC BioPharm.....	313
14.66.1	Gamma Delta T Cells.....	313
14.66.2	Cell Banks.....	314
14.66.3	Co-Stim CAR-T.....	314
14.66.4	Product Pipeline.....	314
14.66.4.1	OmnImmune.....	315
14.66.5	CAR-T Programs.....	315
14.67	T-CURX.....	316
14.67.1	Technologies.....	316
14.68	Umoja Biopharma.....	318
14.68.1	Umoja’s Technology Platforms.....	318
14.68.1.1	VivoVec in vivo Gene Delivery.....	318
14.68.1.2	RACR-Induced Cytotoxic Lymphocytes (iCIL).....	319
14.68.1.3	RACR/CAR: in vivo Cell Programming.....	319
14.68.1.4	TumorTag: Universal CAR Tumor Targeting.....	320
14.69	ViTToria Biotherapeutics.....	321
14.69.1	Senza5.....	321
14.69.2	VIPER-101.....	321
14.70	Vor Biopharma.....	323
14.70.1	Vor Biopharma’s Approach.....	323
14.71	Wugen.....	325
14.72	WuXi Advanced Therapies.....	326
14.72.1	WuXi’s Closed Process CAR-T manufacturing.....	326
14.73	Xenetic Biosciences.....	328
14.73.1	DNase-based Oncology Platform.....	328
14.74	Xyphos Biosciences, Inc.	330
14.74.1	ACCEL & UDC Technology.....	330
14.74.2	convertibleCAR.....	330
14.74.3	Universal Donor Cells.....	331

INDEX OF FIGURES

FIGURE 2.1: The Basic Structure of a T cell..... 22

FIGURE 2.2: Binding of a T cell on to an Infected Cell 23

FIGURE 2.3: Components of a CAT-T cell 24

FIGURE 2.4: The Three Domains of a CAR 25

FIGURE 2.5: First Generation CARs..... 25

FIGURE 2.6: Second Generation CARs 26

FIGURE 2.7: Third Generation CARs..... 26

FIGURE 2.8: Fourth Generation CARs 27

FIGURE 2.9: Fifth Generation CARs..... 28

FIGURE 2.10: Antigens Present on Normal and Cancer Cells 28

FIGURE 2.11: Preparation and Administration of CAR-T cells 31

FIGURE 2.12: Kymriah in Infusion Bag 37

FIGURE 2.13: Yescarta in Infusion Bag 41

FIGURE 2.14: Tecartus in Infusion Bag 44

FIGURE 2.15: Breyanzi in Package 47

FIGURE 2.16: Abecma in the Infusion Bag 52

FIGURE 2.17: Relma-cel in Infusion Bag 54

FIGURE 3.1: Switchable CAR 67

FIGURE 3.2: Action of Suicide Genes 69

FIGURE 3.3: Graphical Abstract for Transient Transfection 70

FIGURE 3.4: A Model of Armored CAR 71

FIGURE 4.1: The Five Generations of CARs 76

FIGURE 6.1: CAR-T Target Antigens Evaluated in Clinical Trials 91

FIGURE 6.1: CAR-T Manufacturing Process Schematics 98

FIGURE 6.2: Local and Centralized Supply Chain Pathways 99

FIGURE 6.2: Scaling up off Allogeneic CAR-T Cells 101

FIGURE 7.1: Number of CAR-T Cell Therapy Patents Filed, 2000-2024 108

FIGURE 8.1: Types of Hematological Cancers Addressed by CAR-T Trials..... 124

FIGURE 8.2: Studies for Simultaneous Targets for One CAR-T 124

FIGURE 8.3: CAR-T Generation Types used in Clinical Trials 125

FIGURE 8.4: CAR-T Trials by Type of SeFv Used 126

FIGURE 8.5: CAR-T Trials by Type of Vectors Used..... 126

FIGURE 8.6: Autologous & Allogeneic CAR-Ts in Clinical Trials..... 127

FIGURE 8.7: Geographical Distribution of CAR-T Clinical Trials for Solid Tumors 129

FIGURE 8.8: Vectors used to Transduce CAR Genes into T Cells for Solid Tumor Studies..... 130

FIGURE 9.1: Number of Published CAR-T Papers on PubMed.gov, 2000-2024 131

FIGURE 9.2: PubMed.gov Papers on Autologous & Allogeneic CAR-T, 2013-2024..... 132

FIGURE 9.3: Number of PubMed.gov Papers on Liquid vs. Solid Cancers, 2013-2024 133

FIGURE 9.4: Percent Shares of the Five Generations of CARs 134

FIGURE 10.1: VC Funding for CAR-T Companies, 2014-2024 139

FIGURE 10.2: IPO Funds Raised by CAR-T Companies, 2014-2024 141

FIGURE 11.1: Total Medicare Spend for CAR-T in OP & IP Setting 159

FIGURE 11.1: Utilization of CAR-T Cell Therapy in Europe 162

FIGURE 11.2: CAR-T Cell Therapy Uptake in Europe by Indication 163

FIGURE 11.3: Cost Breakdown of CAR-T Cell Therapy in Singapore..... 164

FIGURE 13.1: Estimated CAR-T Uptake in Numbers, 2017-2024..... 176

FIGURE 13.2: Revenue Generation by CAR-T Cell Therapies by Product, 2017-2024..... 179

FIGURE 13.3: Global Market for CAR-T Cell Therapy Products, 2024-2032 181

FIGURE 13.4: Global Market for CAR-T Cell Therapy by Geography, 2024-2032..... 183

FIGURE 13.5: Global market Share for CAR-T Therapies by Indication, 2024 184

FIGURE 14.1: Atara's Approach to Allogeneic Cell Therapy 200

FIGURE 14.2: Illustration of CycloCAR-T 219

FIGURE 14.3: Illustration of THANK-uCAR-T	219
FIGURE 14.5: Schematic of Allogeneic P CAR-T with TCR KO	226
FIGURE 14.6: NKG2D-based CAR	228
FIGURE 14.7: Celyad’s Multispecific CAR	228
FIGURE 14.8: CRISPR/Cas9-enabled Allogeneic CAR-T Design	234
FIGURE 14.9: FT819	241
FIGURE 14.10: FT825	242
FIGURE 14.11: FastTCAR vs. Conventional CAR-T Manufacturing Time	245
FIGURE 14.12: Action of TruUCAR	246
FIGURE 14.13: SMART CAR-T	247
FIGURE 14.14: CD19/CD20 CAR-T Technology	252
FIGURE 14.15: TGF- β Bispecific CAR Technology	253
FIGURE 14.16: Lateral CAR	268
FIGURE 14.17: T4 T-Cell	269
FIGURE 14.18: Split Co-Stim Dual CAR	272
FIGURE 14.19: Ligand-Based CAR to Target Three Antigens	273
FIGURE 14.20: Natural Killing of CAR-T Cells	278
FIGURE 14.21: ATx	280
FIGURE 14.22: GTx	281
FIGURE 14.23: STx	282
FIGURE 14.24: VLx	282
FIGURE 14.25: Features of PRIME CAR-T Cell Therapy	288
FIGURE 14.26: BAFFR CAR-T Cells	294
FIGURE 14.27: Poseida’s PiggyBac Platform for Insertion	296
FIGURE 14.28: Poseida’s Cas-CLOVER Platform for Editing	297
FIGURE 14.29: UltraCAR-T Cell	299
FIGURE 14.30: Precigen’s Ultraporator System	300
FIGURE 14.31: Prescient’s OmniCAR	303
FIGURE 14.32: VIPER-101, the Lead Program of ViTToria	322
FIGURE 14.33: WuXi’s Closed Process CAR-T Platform	327
FIGURE 14.34: Convertible CAR Parts	331
FIGURE 14.35: Xyphos’ Universal Donor Cells	331

INDEX OF TABLES

TABLE 2.1: Potential Antigens Present on Hematological Malignant Cells	29
TABLE 2.2: Key Differences between the Available Vectors	30
TABLE 2.3: The 13 CAR-T Therapies Available Globally	32
TABLE 2.3: (CONTINUED)	33
TABLE 2.3: (CONTINUED)	34
TABLE 2.3: (CONTINUED)	35
TABLE 2.4: Acquisition Cost of CAR-T Therapy Products around the World	64
TABLE 3.1: Strategies for Future CAR-T Therapies	66
TABLE 3.2: A Sample of Clinical Studies on Solid Cancers	73
TABLE 3.3: New Target Antigens and New Target Cancers	74
TABLE 4.1: History of CAR-T Therapy Development	77
TABLE 4.2: Upcoming CAR-T Stars	84
TABLE 4.3: The Small Cancer Population Addressed by CAR-T Therapy	88
TABLE 5.1: CAR-T Target Antigens in Hematological Cancers	92
TABLE 5.2: Select CAR-T Target Antigens in Clinical Trials	93
TABLE 5.3: Targeted Antigens by Approved CAR-Ts	94
TABLE 6.2: Key Process Metrics with Increasing Levels of Automation	106
TABLE 6.3: Breakdown of CAR-T Manufacturing Cost	107

TABLE 7.1: Geographical Distribution of CAR-T Cell Therapy Patents.....	109
TABLE 7.2: CAR-T Cell Therapy Patent Applicants.....	110
TABLE 7.2: (CONTINUED)	111
TABLE 7.2: (CONTINUED)	112
TABLE 7.3: Top 100 CAR-T Patent Inventors.....	113
TABLE 7.3: (CONTINUED)	114
TABLE 7.3: (CONTINUED)	115
TABLE 7.4: Top 100 CAR-T Cell Therapy Patent Owners	116
TABLE 7.4: (CONTINUED)	117
TABLE 7.4: (CONTINUED)	118
TABLE 7.5: Legal Status of CAR-T Therapy Patents.....	119
TABLE 8.1: CAR-T Clinical Trials by Phase of Development, January 15, 2025	122
TABLE 8.2: Types of CAR-T Clinical Trials.....	122
TABLE 8.3: CAR-T Clinical Trials by Funding Type.....	123
TABLE 8.4: CAR-T for Solid Cancers: An Overview of Data	128
TABLE 10.1: Venture Capital Funding in CAR-T Sector, 2014-2024.....	136
TABLE 10.1: (CONTINUED)	137
TABLE 10.1: (CONTINUED)	138
TABLE 10.2: IPOs by CAR-T Cell Therapy Companies, 2014-2024	140
TABLE 10.2: (CONTINUED)	141
TABLE 10.3: CAR-T Licencing Deals, 2015-2024	142
TABLE 10.3: (CONTINUED)	143
TABLE 10.3: (CONTINUED)	144
TABLE 10.3: (CONTINUED)	145
TABLE 10.4: CAR-T Collaboration Deals, 2013-2024	145
TABLE 10.4: (CONTINUED)	146
TABLE 10.4: (CONTINUED)	147
TABLE 10.4: (CONTINUED)	148
TABLE 10.5: CAR-T Merger & Acquisition (M&A) Deals, 2015-2024	149
TABLE 10.5: (CONTINUED)	150
TABLE 10.6: Summary of CAR-T Funding, 2014-2024	151
TABLE 11.1: List Prices of CAR-T Cells	153
TABLE 11.2: Pre-, Peri- & Post Infusion Unit Costs.....	155
TABLE 11.3: Adverse Events Rates & Unit Costs of Management	156
TABLE 11.4: Reimbursement for CAR-T Cases, 2024 vs. 2025	158
TABLE 11.5: EU-Approved CAR-T Cell Therapies	160
TABLE 11.7: Approximate Cost of CAR-T Cell Therapies in Select E.U. Countries.....	161
TABLE 12.1: Available Therapies for ALL.....	168
TABLE 12.2: Available Therapies for DLBCL.....	169
TABLE 12: Available Therapies for MCL.....	170
TABLE 12.4: Approved Therapies for Multiple Myeloma	172
TABLE 12.5 Available Therapies for Follicular Lymphoma (FL)	172
TABLE 12.6: The Staggering Cost of Blood Cancer Therapies	174
TABLE 13.2: Revenue Generation by CAR-T Cell Therapies by Product, 2017-2024	179
TABLE 13.3: Global Market for CAR-T Cell Therapy Products, 2024-2032	181
TABLE 13.4: Global Market for CAR-T Therapy by Geography, 2024-2032	183
TABLE 13.5: Global Market for CAR-T Therapies by Indication, 2024-2032.....	184
TABLE 14.1: AffyImmune’s Affinity-Tuned Pipeline Products	192
TABLE 14.2: Aleta’s CAR-T Engager Pipeline.....	193
TABLE 14.3: Allogene’s AlloCAR-T Pipeline.....	195
TABLE 14.4: Anixa’s CAR-T Pipeline.....	196
TABLE 14.5: Arbele’s Advanced Cell Therapy Product Candidates	197
TABLE 14.6: ArcellIX’s Current Product Pipeline	199
TABLE 14.7: Atara’s Product Pipeline.....	201
TABLE 14.8: Autolus’ Therapies in Development	204
TABLE 14.9: Clinical & Preclinical Pipeline Overview	206

TABLE 14.10: Bellicum’s Pipeline	209
TABLE 14.11: BRiDGE CAR Program	211
TABLE 14.12: Cabaletta’s Autoimmune Therapy Candidates in Development	216
TABLE 14.13: Carina’s Clinical Programs.....	217
TABLE 14.14: CARsgen’s Product Pipeline	220
TABLE 14.15: Cartesian’s Product Pipeline	222
TABLE 14.16: Cellectis’ Allogeneic CAR-T Cell Product Pipeline	225
TABLE 14.17: CRISPR Therapeutics’ CAR-T Programs	234
TABLE 14.18: Elicera’s Product Pipeline	238
TABLE 14.19: EXUMA’s Pipeline Assets	240
TABLE 14.20: Galapagos’ Oncology CAR-T Pipeline.....	243
TABLE 14.21: Gracell’s Rich Product Pipeline.....	248
TABLE 14.22: IASO’s Diverse Product Pipeline	251
TABLE 14.23: ImmPACT Bio’s Product Pipeline	253
TABLE 14.24: Immuneels Product Pipeline	254
TABLE 14.25: JW Therapeutics’ Product Pipeline	259
TABLE 14.26: Kite’s Pipeline Cancer Therapies.....	262
TABLE 14.27: Product Pipeline to address Autoimmune Diseases.....	263
TABLE 14.28: Legend Biotech’s Product Pipeline	266
TABLE 14.29: Leucid’s Product Pipeline.....	270
TABLE 14.30: Luminary’s Product Pipeline	274
TABLE 14.31: Lyell’s Product Pipeline	276
TABLE 14.32: March Biosciences’ Product Pipeline.....	278
TABLE 14.33: A Comparison Guide for MaxCyte’s Electroporation Systems	283
TABLE 14.34: Minerva’s CAR-T Pipeline Products for Solid Tumors	285
TABLE 14.35: Mustang’s CAR-T Product Candidates	286
TABLE 14.36: Noile-Immune’s PRIME-Based Product Pipeline	288
TABLE 14.37: Oxford Biomedica’s CDMO Services	293
TABLE 14.38: PeproMene’s Product Pipeline.....	295
TABLE 14.39: Poseida’s CAR-T Product Pipeline	298
TABLE 14.40: Precigen’s UltraCAR-T Pipeline.....	301
TABLE 14.41: Prescient’s CAR-T Pruct Pipeline	303
TABLE 14.42: ProMabs CAR-T Cells.....	305
TABLE 14.43: ProMab’s Discovery Services Plans & Prices.....	306
TABLE 14.44: Synthekine’s Pipeline with SYNCAR-001 + STK-009.....	312
TABLE 14.45: T-CURX’ Product Candidates in Clinical Trials.....	317
TABLE 14.46: Umoja’s Product Pipeline	320
TABLE 14.47: Vor Biopharma’s Current Product Pipeline	324
TABLE 14.48: Wugen’s Product Pipeline	325
TABLE 14.49: Xenetic’s CAR-T Product Pipeline	329

About BioInformant:

Founded in 2006, BioInformant is the world's first and only market research firm to specialize in the cell therapy industry.

Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, and Capitol Hill, BioInformant has collected 19+ years of historical data, providing a robust and unusual foundation on which to base its market research and make future market forecasts.

BioInformant's team of analysts operate one of the world's largest cell therapy industry news sites, BioInformant.com, attracting nearly one million readers per year.

